

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Characterization of the Binding of a Novel Non-Xanthine Adenosine Antagonist Radioligand, [³H]CGS 15943, to Multiple Affinity States of the Adenosine A₁ Receptor in the Rat Cortex

Michael F. Jarvis^{ab}; Michael Williams^{ac}; Un Hoi Do^d; Matthew A. Sills^a

^a Research Department, Pharmaceuticals Division, CIBA-GEIGY Corp., NJ ^b Rorer Central Research, King of Prussia, PA ^c Abbott Laboratories, IL ^d Dupont-NEN Products, Boston, MA

To cite this Article Jarvis, Michael F. , Williams, Michael , Do, Un Hoi and Sills, Matthew A.(1991) 'Characterization of the Binding of a Novel Non-Xanthine Adenosine Antagonist Radioligand, [³H]CGS 15943, to Multiple Affinity States of the Adenosine A₁ Receptor in the Rat Cortex', Nucleosides, Nucleotides and Nucleic Acids, 10: 5, 1201 – 1202

To link to this Article: DOI: 10.1080/07328319108047275

URL: <http://dx.doi.org/10.1080/07328319108047275>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

CHARACTERIZATION OF THE BINDING OF A NOVEL NON-XANTHINE
ADENOSINE ANTAGONIST RADIOLIGAND, [³H]CGS 15943,
TO MULTIPLE AFFINITY STATES OF THE ADENOSINE A₁ RECEPTOR
IN THE RAT CORTEX

Michael F. Jarvis*, Michael Williams**, Un Hoi Do***
and Matthew A. Sills

Research Department, Pharmaceuticals Division,
CIBA-GEIGY Corp. Summit, NJ 07901 and
***Dupont-NEN Products, Boston, MA 02118

The use of xanthine adenosine receptor antagonists such as 1,3-dipropyl-8-phenylxanthine (DPX) as radioligands for the characterization of adenosine receptor pharmacology have been limited by their high lipophilicity, low specific activity, and their general lack of selectivity and affinity for adenosine receptors¹. Recent attempts to address the technical problems associated with this class of compounds has resulted in the development of several xanthine derivatives (e.g. the functionalized xanthine congeners [³H]XCC and [³H]XAC², and [³H]CPX³) which bind with high and selective affinity to the adenosine A₁ receptor subtype. Based on efforts to optimize non-xanthine adenosine receptor antagonists⁴, CGS 15943, a derivative of the pyrazoloquinazoline benzodiazepine receptor inverse agonist CGS 8216⁵, represents the first reported non-xanthine structure that potently blocks adenosine receptors⁶. CGS 15943 has nanomolar affinity for both A₁ and A₂ receptor subtypes⁶. However, in contrast to many of the xanthine adenosine receptor antagonists, CGS 15943 is not a phosphodiesterase inhibitor and does not interact with adenosine transporter sites⁶. This compound is a potent and selective adenosine receptor antagonist *in vivo*⁷ with a solubility/affinity ratio of greater than 1000⁷. In the present studies, the binding of [³H]CGS 15943 to the adenosine A₁ receptor was characterized.

*Present Address: Rorer Central Research, 680 Allendale Road,
King of Prussia, PA 19046

**Present Address: Abbott Laboratories, Abbott Park, IL 60064

Ligand saturation experiments revealed the [^3H]CGS 15943 labeled a single class of recognition sites with high affinity ($K_d = 4 \text{ nM}$) and limited capacity ($B_{\text{max}} = 1.5 \text{ pmol/mg protein}$). Competition experiments revealed that the binding of [^3H]CGS 15943 was consistent with the labeling of the A_1 receptor subtype. Adenosine agonists inhibited 1 nM [^3H]CGS 15943 binding with the following potency order: CPA ($\text{IC}_{50} = 15 \text{ nM}$) > 2-CADO > R-PIA > NECA > S-PIA > CGS 21680 > CV 1808 ($\text{IC}_{50} > 10,000 \text{ nM}$). The potency order for adenosine antagonists was CGS 15943 ($\text{IC}_{50} = 5 \text{ nM}$) > 8-PT > PACPX > DPX > theophylline = caffeine ($\text{IC}_{50} > 10,000 \text{ nM}$). Antagonist inhibition curves were steep and best described by a one-site binding model. In contrast, A_1 agonist competition curves were shallow. Computer analysis revealed that these inhibition curves were best described by a two-site binding model. Agonist competition curves generated in the presence of 1 mM GTP resulted in a rightward shift and steepening of the inhibition-concentration curves while antagonist binding was not affected. The complex binding interactions found with adenosine agonists indicate that [^3H]CGS 15943 labels both high and low affinity components of the adenosine A_1 receptor in the rat cortex. Thus [^3H]CGS 15943 represents the first radiolabeled non-xanthine adenosine antagonist which can be used to characterize multiple affinity states of the brain A_1 receptor.

References

1. Bruns, R.F., Daly, J.W., Snyder, S.H. Proc. Natl. Acad. Sci. 77: 5547, 1980.
2. Jacobson, K.A., Ukena, D., Kirk, K.L., Daly, J.W. Proc. Natl. Acad. Sci. 83: 4089, 1986.
3. Bruns, R.F., Fergus, J.H., Badger, E.W., Bristol, J.A., Santay, L.A., Hartman, J.D., Hays, S.J., Huang, C.C. Naunyn-Schmiedeberg's Arch. Pharmacol. 335: 59, 1987.
4. Francis, J., Cash, W., Psychoyos, S., Ghai, G., Wenk, P., Friedmann, R., Atkins, C., Warren, V., Furness, P., Hyun, J., Stone, G., Desai, M., Williams, M. J. Med. Chem. 31: 1014, 1988.
5. Yokoyama, N., Ritter, B., Neubert, A. J. Med. Chem. 25: 337, 1982.
6. Williams, M., Francis, J., Ghai, G., Braunwalder, A., Psychoyos, S., Stone, G., Cash, W. J. Pharmacol. Exp. Ther. 241: 415, 1987.
7. Bruns, R.H. and Fergus, J. J. Pharm. Pharmacol. 41: 590, 1989.